Patents by Inventor Michael J. Hadd

Michael J. Hadd has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • PHARMACEUTICAL FORMULATIONS
    Publication number: 20240139109
    Abstract: The pharmacokinetic profile of the SGLT2 inhibitor bexagliflozin can be improved by formulating it as an extended release tablet. Compared with standard immediate-release dosage forms these tablets can permit a lower peak plasma concentration, Cmax, while maintaining plasma concentrations at therapeutic levels for a desired period. This can be used, for instance, to administer lower doses while still providing the same pharmacological effect.
    Type: Application
    Filed: November 3, 2023
    Publication date: May 2, 2024
    Inventors: Feng WANG, Ankit SHRIVASTAVA, Rina SHAH, Brian SEED, Vinay PATIL, Michael J. HADD, Fuxia DONG, Vipan DHALL, Chunfeng DAI, Joseph Ho-Lun CHAU, Qiuhua CAI
  • VETERINARY PHARMACEUTICAL FORMULATIONS
    Publication number: 20230372374
    Abstract: Provided herein are oral immediate release formulations of bexagliflozin for administration to companion animals.
    Type: Application
    Filed: May 16, 2023
    Publication date: November 23, 2023
    Inventors: Ning LI, Michael J. HADD, Brian SEED, Gopinath DEVARAJ, Esther SEE, Su WIN
  • PHARMACEUTICAL FORMULATIONS
    Publication number: 20220117898
    Abstract: The pharmacokinetic profile of the SGLT2 inhibitor bexagliflozin can be improved by formulating it as an extended release tablet. Compared with standard immediate-release dosage forms these tablets can permit a lower peak plasma concentration, Cmax, while maintaining plasma concentrations at therapeutic levels for a desired period. This can be used, for instance, to administer lower doses while still providing the same pharmacological effect.
    Type: Application
    Filed: October 5, 2021
    Publication date: April 21, 2022
    Inventors: Feng WANG, Ankit SHRIVASTAVA, Rina SHAH, Brian SEED, Vinay PATIL, Michael J. HADD, Fuxia DONG, Vipan DHALL, Chunfeng DAI, Joseph Ho-Lun CHAU, Qiuhua CAI
  • Heterocyclic compounds and methods of use thereof
    Patent number: 9938261
    Abstract: Provided herein are heterocyclic compounds for treatment of CSF1R, FLT3, KIT, and/or PDGFR? kinase mediated diseases. Also provided are pharmaceutical compositions comprising the compounds and methods of using the compounds and compositions.
    Type: Grant
    Filed: June 20, 2016
    Date of Patent: April 10, 2018
    Assignee: Ambit Biosciences Corporation
    Inventors: Michael J. Hadd, Michael D. Hocker, Mark W. Holladay, Gang Liu, Martin W. Rowbottom, Shimin Xu
  • HETEROCYCLIC COMPOUNDS AND METHODS OF USE THEREOF
    Publication number: 20160362405
    Abstract: Provided herein are heterocyclic compounds for treatment of CSF1R, FLT3, KIT, and/or PDGFR? kinase mediated diseases. Also provided are pharmaceutical compositions comprising the compounds and methods of using the compounds and compositions.
    Type: Application
    Filed: June 20, 2016
    Publication date: December 15, 2016
    Inventors: Michael J. Hadd, Michael D. Hocker, Mark W. Holladay, Gang Liu, Martin W. Rowbottom, Shimin Xu
  • Heterocyclic compounds and methods of use thereof
    Patent number: 9452167
    Abstract: Provided herein are heterocyclic compounds for treatment of CSF1R, FLT3, KIT, and/or PDGFR? kinase mediated diseases. Also provided are pharmaceutical compositions comprising the compounds and methods of using the compounds and compositions.
    Type: Grant
    Filed: December 22, 2014
    Date of Patent: September 27, 2016
    Assignee: AMBIT BIOSCIENCES CORPORATION
    Inventors: Michael J. Hadd, Michael D. Hocker, Mark W. Holladay, Gang Liu, Martin W. Rowbottom, Shimin Xu
  • JAK kinase modulating compounds and methods of use thereof
    Patent number: 9308207
    Abstract: Provided herein are quinazoline compounds of formula (I): The compounds are useful for treatment of JAK kinase mediated diseases, including JAK2 kinase-, JAK3 kinase- or TYK2 kinase-mediated diseases. Also provided are pharmaceutical compositions comprising the compounds and methods of using the compounds and compositions.
    Type: Grant
    Filed: December 2, 2014
    Date of Patent: April 12, 2016
    Assignee: Ambit Biosciences Corp.
    Inventors: Sunny Abraham, Qi Chao, Michael J. Hadd, Mark W. Holladay, Gang Liu, Eduardo Setti
  • HETEROCYCLIC COMPOUNDS AND METHODS OF USE THEREOF
    Publication number: 20150196566
    Abstract: Provided herein are heterocyclic compounds for treatment of CSF1R, FLT3, KIT, and/or PDGFR? kinase mediated diseases. Also provided are pharmaceutical compositions comprising the compounds and methods of using the compounds and compositions.
    Type: Application
    Filed: December 22, 2014
    Publication date: July 16, 2015
    Applicant: AMBIT BIOSCIENCES CORPORATION
    Inventors: Michael J. Hadd, Michael D. Hocker, Mark W. Holladay, Gang Liu, Martin W. Rowbottom, Shimin Xu
  • JAK KINASE MODULATING COMPOUNDS AND METHODS OF USE THEREOF
    Publication number: 20150150874
    Abstract: Provided herein are quinazoline compounds for treatment of JAK kinase mediated diseases, including JAK2 kinase-, JAK3 kinase- or TYK2 kinase-mediated diseases. Also provided are pharmaceutical compositions comprising the compounds and methods of using the compounds and compositions.
    Type: Application
    Filed: December 2, 2014
    Publication date: June 4, 2015
    Applicant: Ambit Biosciences Corp.
    Inventors: Sunny Abraham, Qi Chao, Michael J. Hadd, Mark W. Holladay, Gang Liu, Eduardo Setti
  • Heterocyclic compounds and methods of use thereof
    Patent number: 8952058
    Abstract: Provided herein are heterocyclic compounds for treatment of CSF1R, FLT3, KIT, and/or PDGFR? kinase mediated diseases. Also provided are pharmaceutical compositions comprising the compounds and methods of using the compounds and compositions.
    Type: Grant
    Filed: October 12, 2012
    Date of Patent: February 10, 2015
    Assignee: Ambit Biosciences Corporation
    Inventors: Michael J. Hadd, Michael D. Hocker, Mark W. Holladay, Gang Liu, Martin W. Rowbottom, Shimin Xu
  • JAK kinase modulating compounds and methods of use thereof
    Patent number: 8927711
    Abstract: Provided herein are quinazoline compounds of formula (I): The compounds are useful for treatment of JAK kinase mediated diseases, including JAK2 kinase-, JAK3 kinase- or TYK2 kinase-mediated diseases. Also provided are pharmaceutical compositions comprising the compounds and methods of using the compounds and compositions.
    Type: Grant
    Filed: October 4, 2012
    Date of Patent: January 6, 2015
    Assignee: Ambit Biosciences Corp.
    Inventors: Sunny Abraham, Qi Chao, Michael J. Hadd, Mark W. Holladay, Gang Liu, Eduardo Setti
  • Benzylbenzene derivatives and methods of use
    Patent number: 8802637
    Abstract: Provided are compounds having an inhibitory effect on sodium-dependent glucose cotransporter SGLT. The invention also provides pharmaceutical compositions, methods of preparing the compounds, synthetic intermediates, and methods of using the compounds, independently or in combination with other therapeutic agents, for treating diseases and conditions which are affected by SGLT inhibition.
    Type: Grant
    Filed: September 30, 2013
    Date of Patent: August 12, 2014
    Assignee: Theracos, Inc.
    Inventors: Yuanwei Chen, Huawei Cheng, Shengbin Li, Yuelin Wu, Yan Feng, Binhua Lv, Binhua Xu, Brian Seed, Michael J. Hadd, Yanli Song, Jiyan Du, Congna Wang, Jacques Y. Roberge
  • BENZYLBENZENE DERIVATIVES AND METHODS OF USE
    Publication number: 20140031300
    Abstract: Provided are compounds having an inhibitory effect on sodium-dependent glucose cotransporter SGLT. The invention also provides pharmaceutical compositions, methods of preparing the compounds, synthetic intermediates, and methods of using the compounds, independently or in combination with other therapeutic agents, for treating diseases and conditions which are affected by SGLT inhibition.
    Type: Application
    Filed: September 30, 2013
    Publication date: January 30, 2014
    Applicant: Theracos, Inc.
    Inventors: Yuanwei Chen, Huawei Cheng, Shengbin Li, Yuelin Wu, Yan Feng, Binhua Lv, Baihua Xu, Brian Seed, Michael J. Hadd, Yanli Song, Jiyan Du, Congna Wang, Jacques Y. Roberge
  • Quinazoline compounds and methods of use thereof
    Patent number: 8633207
    Abstract: Provided herein are quinazoline compounds for treatment of JAK kinase mediated diseases, including JAK2 kinase-, JAK3 kinase- or TYK2 kinase-mediated diseases. Also provided are pharmaceutical compositions comprising the compounds and methods of using the compounds and compositions.
    Type: Grant
    Filed: August 31, 2011
    Date of Patent: January 21, 2014
    Assignee: Ambit Biosciences Corporation
    Inventors: Michael J. Hadd, Mark W. Holladay, Martin Rowbottom
  • THIENOPYRIDINE AND THIENOPYRIMIDINE COMPOUNDS AND METHODS OF USE THEREOF
    Publication number: 20130317045
    Abstract: Provided herein are thienopyridine and thienopyrimidine compounds of formula (I) for treatment of JAK kinase mediated diseases, including JAK2 kinase-, JAK3 kinase- or TYK2 kinase-mediated diseases. Also provided are pharmaceutical compositions comprising the compounds and methods of using the compounds and compositions.
    Type: Application
    Filed: August 31, 2011
    Publication date: November 28, 2013
    Applicant: AMBIT BIOSCIENCES CORPORATION
    Inventors: Michael J. Hadd, Mark W. Holladay, Eduardo Setti
  • AZOLOPYRIDINE AND AZOLOPYRIMIDINE COMPOUNDS AND METHODS OF USE THEREOF
    Publication number: 20130303533
    Abstract: Provided herein are azolopyridine and azolopyrimidine compounds for treatment of JAK kinase mediated diseases, including JAK2 kinase-, JAK3 kinase- or TYK2 kinase-mediated diseases. Also provided are pharmaceutical compositions comprising the compounds and methods of using the compounds and compositions.
    Type: Application
    Filed: August 31, 2011
    Publication date: November 14, 2013
    Applicant: AMBIT BIOSCIENCES CORPORATION
    Inventors: Qi Chao, Michael J. Hadd, Mark W. Holladay, Martin Rowbottom
  • QUINOLINE AND ISOQUINOLINE DERIVATIVES FOR USE AS JAK MODULATORS
    Publication number: 20130296363
    Abstract: Provided herein are compounds for treatment of JAK kinase mediated diseases, including JAK2 kinase-, JAK3 kinase- or TYK2 kinase-mediated diseases. Also provided are pharmaceutical compositions comprising the compounds and methods of using the compounds and compositions.
    Type: Application
    Filed: August 31, 2011
    Publication date: November 7, 2013
    Applicant: AMBIT BIOSCIENCES CORPORATION
    Inventors: Raffaella Faraoni, Michael J. Hadd, Mark W. Holladay, Martin W. Rowbottom, Eduardo Setti
  • JAK KINASE MODULATING COMPOUNDS AND METHODS OF USE THEREOF
    Publication number: 20130245014
    Abstract: Provided herein are quinazoline compounds for treatment of JAK kinase mediated diseases, including JAK2 kinase-, JAK3 kinase- or TYK2 kinase-mediated diseases. Also provided are pharmaceutical compositions comprising the compounds and methods of using the compounds and compositions.
    Type: Application
    Filed: October 4, 2012
    Publication date: September 19, 2013
    Applicant: Ambit Biosciences Corp.
    Inventors: Sunny Abraham, Qi Chao, Michael J. Hadd, Mark W. Holladay, Liu Gang, Eduardo Setti
  • 4-AZOLYLAMINOQUINAZOLINE DERIVATIVES AND METHODS OF USE THEREOF
    Publication number: 20130225614
    Abstract: Provided herein are 4-azolylaminoquinazoline compounds for treatment of JAK kinase mediated diseases, including JAK2 kinase-, JAK3 kinase- or TYK2 kinase-mediated diseases. Also provided are pharmaceutical compositions comprising the compounds and methods of using the compounds and compositions.
    Type: Application
    Filed: August 31, 2011
    Publication date: August 29, 2013
    Applicant: Ambit Biosciences Corporation
    Inventor: Michael J. Hadd
  • 2-CYCLOQUINAZOLINE DERIVATIVES AND METHODS OF USE THEREOF
    Publication number: 20130225615
    Abstract: Provided herein are 2-cycloquinazoline compounds for treatment of JAK kinase mediated diseases, including JAK2 kinase-, JAK3 kinase- or TYK2 kinase-mediated diseases. Also provided are pharmaceutical compositions comprising the compounds and methods of using the compounds and compositions.
    Type: Application
    Filed: August 31, 2011
    Publication date: August 29, 2013
    Applicant: AMBIT BIOSCIENCES CORPORATION
    Inventor: Michael J. Hadd